Aptamer Group (LSE:APTA) expects to report higher revenue for the 2026 financial year, supported by continued demand for its fee-for-service activities and the first licensing income generated from commercial agreements.
The life sciences company also recorded significant growth in its sales pipeline, providing improved visibility over future revenue as it expands adoption of its Optimer technology platform.
Licensing Income Supports Revenue Increase
The company expects FY2026 revenue of approximately £1.5 million, representing a 25% increase from the previous year.
Growth was driven by a combination of contract research work and initial licensing revenue from partnerships with Twist Bioscience and Alphazyme, marking an important step in Aptamer’s strategy to increase higher-margin recurring income.
The commercial pipeline expanded by 55% to £4.8 million during the year, while the FY2027 order book reached approximately £0.6 million, reflecting growing customer interest in the company’s Optimer platform.
Partnerships and Platform Investment Continue
Aptamer continued to strengthen its commercial relationships during the year, advancing projects with several leading global pharmaceutical companies alongside programmes spanning diagnostics, food testing and radiopharmaceutical development.
The company also continued investing in artificial intelligence-enabled discovery tools and greater automation across its technology platform to improve efficiency and accelerate product development.
Management believes licensing will become an increasingly important contributor to future earnings as additional commercial agreements are secured.
Funding Extends Cash Runway
Following a fundraising completed in April 2026, Aptamer said it has sufficient funding to support operations until at least 2028.
The strengthened financial position allows the company to continue investing in product development, commercial expansion and platform enhancements while pursuing additional licensing opportunities during FY2027.
Financial Challenges Remain
Despite improving commercial momentum, Aptamer continues to operate at a loss and remains affected by negative cash flow.
Technical indicators also remain weak, with the shares trading below key moving averages and broader market momentum remaining negative, although oversold conditions provide some support.
Valuation also continues to be constrained by negative earnings and the absence of a dividend.
About Aptamer Group Plc
Aptamer Group Plc is a life sciences company developing synthetic Optimer binders for use in diagnostics, therapeutics and research applications.
The company works with pharmaceutical and biotechnology partners to integrate its platform into diagnostic assays, enzyme technologies and emerging therapeutic programmes, while expanding its focus on higher-value licensing opportunities and proprietary asset development.
Leave a Reply